INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer's Disease and NASH
Stock Information for INmune Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.